Au Catalyzing Control Release NO in vivo and Tumor Growth-Inhibiting Effect in Chemo-Photothermal Combination Therapy

Abstract

Introduction:Aim to obtain a NO donor that can control released NO in vivo with the high efficacy of tumor suppression and targeting, a nanoplatform consisting of FA-Fe 3 O 4 @mSiO 2 -Au/DOX was constructed. Methods: In vitro, the nanoplatform catalyzed NO's release with the maximum value of 4.91 μM within 60 min at 43°C pH=5.0, which was increased by 1.14 times when the temperature was 37°C. In vivo, 11.7 μg Au in the tumor tissue was found to catalyze S-nitrosoglutathione continuously, and 54 μM NO was checked out in the urine. Results and Discussion: The high concentration of NO was found to increase the apoptotic rate and to reduce tumor proliferation. In the chemo-photothermal combination therapy, the tumor inhibition rate was increased up to 94.3%, and Au's contribution from catalyzing NO release NO was 8.17%.

Nanocatalysts for modulating antitumor immunity: fabrication, mechanisms and applications

“…For example, Au nanoparticles were employed to catalyze the production of NO from thermal-sensitive NO prodrugs under laser irradiation for tumor treatment. 230 Besides Au, other noble metals (Ag, Pt, Pd and Ru) have also shown catalytic activity, such as OXD-like activity, POD-like activity, SOD-like activity, and CAT-like activity. 45,[231][232][233] The enzyme-like activity of these nanomaterials depends on environmental conditions, such as pH and reaction substrates.…”

“…For example, Au nanoparticles were employed to catalyze the production of NO from thermal-sensitive NO prodrugs under laser irradiation for tumor treatment. 230…”

An Update on Mesoporous Silica Nanoparticle Applications in Nanomedicine

“…However, the effectiveness of traditional chemotherapy is limited by its poor selectivity, poor aqueous solubility, high systemic toxicity, and multidrug resistance [ 91 , 366 , 367 ]. MSNs have emerged as a potential drug delivery system that can both improve chemotherapy on its own [ 368 , 369 , 370 ] as well as in combination with other cancer therapies [ 90 , 371 , 372 ]. One of the major challenges of chemotherapy is the multidrug resistance (MDR) that is commonly attributed to the overexpression of the transmembrane efflux pump P-glycoprotein (P-gp) in cancer cells.…”